133 related articles for article (PubMed ID: 23501104)
1. Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models.
Sakamoto T; Ozaki K; Fujio K; Kajikawa SH; Uesato S; Watanabe K; Tanimura S; Koji T; Kohno M
Biochem Biophys Res Commun; 2013 Apr; 433(4):456-62. PubMed ID: 23501104
[TBL] [Abstract][Full Text] [Related]
2. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.
Watanabe K; Tanimura S; Uchiyama A; Sakamoto T; Kawabata T; Ozaki K; Kohno M
Clin Cancer Res; 2010 Feb; 16(4):1170-8. PubMed ID: 20145173
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death.
Ozaki K; Minoda A; Kishikawa F; Kohno M
Biochem Biophys Res Commun; 2006 Jan; 339(4):1171-7. PubMed ID: 16338224
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
Ozaki K; Kosugi M; Baba N; Fujio K; Sakamoto T; Kimura S; Tanimura S; Kohno M
Biochem Biophys Res Commun; 2010 Jan; 391(4):1610-5. PubMed ID: 20026060
[TBL] [Abstract][Full Text] [Related]
5. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Koeffler HP; Yokoyama A
Leukemia; 2008 Dec; 22(12):2159-68. PubMed ID: 18784743
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
7. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
8. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
Haass NK; Sproesser K; Nguyen TK; Contractor R; Medina CA; Nathanson KL; Herlyn M; Smalley KS
Clin Cancer Res; 2008 Jan; 14(1):230-9. PubMed ID: 18172275
[TBL] [Abstract][Full Text] [Related]
9. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
10. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell.
Nishioka C; Ikezoe T; Yang J; Koeffler HP; Yokoyama A
Leukemia; 2008 Jul; 22(7):1449-52. PubMed ID: 18185526
[No Abstract] [Full Text] [Related]
14. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
McDaid HM; Lopez-Barcons L; Grossman A; Lia M; Keller S; PĂ©rez-Soler R; Horwitz SB
Cancer Res; 2005 Apr; 65(7):2854-60. PubMed ID: 15805287
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
18. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
19. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]